このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Cann Group 過去の業績

過去基準チェック /06

Cann Groupの収益は年間平均-24.3%の割合で減少していますが、 Pharmaceuticals業界の収益は年間増加しています。収益は年間35.6% 47.2%割合で増加しています。

主要情報

-24.3%

収益成長率

0.3%

EPS成長率

Pharmaceuticals 業界の成長	31.2%
収益成長率	47.2%
株主資本利益率	-58.2%
ネット・マージン	-137.2%
前回の決算情報	31 Dec 2023

Recent updates

Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now

Nov 03

Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn Situation

Feb 23

What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Nov 25

One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To Be

Nov 25

収支内訳

Cann Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

ASX:CAN 収益、費用、利益 ( )AUD Millions
日付	収益	収益	G+A経費	研究開発費
31 Dec 23	21	-29	35	2
30 Sep 23	21	-32	35	3
30 Jun 23	21	-34	34	4
31 Mar 23	18	-35	28	4
31 Dec 22	14	-37	27	5
30 Sep 22	13	-32	27	4
30 Jun 22	11	-26	28	3
31 Mar 22	10	-25	27	2
31 Dec 21	9	-24	26	2
30 Sep 21	9	-25	25	2
30 Jun 21	9	-25	23	2
31 Mar 21	7	-22	19	2
31 Dec 20	6	-18	15	2
30 Sep 20	4	-17	14	2
30 Jun 20	2	-17	14	1
31 Mar 20	2	-16	15	1
31 Dec 19	3	-14	16	1
30 Sep 19	3	-13	15	1
30 Jun 19	3	-11	13	1
31 Mar 19	2	-10	11	1
31 Dec 18	1	-8	9	1
30 Sep 18	1	-6	7	1
30 Jun 18	1	-5	6	1
31 Mar 18	0	-4	4	1
31 Dec 17	0	-3	2	0
30 Sep 17	0	-3	2	1
30 Jun 17	0	-3	2	1
30 Jun 16	0	-1	1	0
30 Jun 15	0	-4	4	0

質の高い収益: CANは現在利益が出ていません。

利益率の向上: CANは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: CANは利益が出ておらず、過去 5 年間で損失は年間24.3%の割合で増加しています。

成長の加速: CANの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: CANは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 28.2% ) と比較することは困難です。

株主資本利益率

高いROE: CANは現在利益が出ていないため、自己資本利益率 ( -58.21% ) はマイナスです。

Cann Group 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)

First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)

Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: AU$0.097 loss per share (vs AU$0.12 loss in FY 2020)

First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.06 loss in 1H 2020)

Recent updates

Less than half of directors are independent

Cann Group Limited's (ASX:CAN) Low P/S No Reason For Excitement

New major risk - Financial position

Cann Group Limited Appoints Tony Di Pietro as Joint Company Secretary of Head of Legal and Regulatory Affairs

A Piece Of The Puzzle Missing From Cann Group Limited's (ASX:CAN) Share Price

Cann Group Limited Announces Resignation of Deborah Ambrosini as Chief Financial Officer, Effective December 22, 2023

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million.

Cann Group Limited, Annual General Meeting, Oct 26, 2023

Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)

New minor risk - Financial data availability

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million.

Cann Group Limited Provides Revenue Guidance for the Year Ended June 30, 2023

Cann Group (ASX:CAN) Is Making Moderate Use Of Debt

First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)

Cann Group Limited Announces Preliminary Results from Their Phase 3 Clinical Trail

Cann Group Limited Announces Chief Executive Officer Changes

Cann Group Limited Announces Final Clinical Trial Participant Completes Study

Less than half of directors are independent

Cann Group Limited Appoints Julian John Chick as Director

Cann Group Limited Announces Resignation of Peter Crock as CEO

Cann Group Limited Meets its Enrolment Target for Phase III Clinical Trial of Low-Dose Satipharm CBD Capsules for Short-Term Sleep Disturbance

Cann Group Limited Announces Executive Changes

Cann Group Limited Appoints Robert Barnes & Julian Chick to the Board

Cann Group Limited Announces Resignation of John Sharman as Director

Cann Group Limited, Annual General Meeting, Oct 25, 2022

Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)

Cann Group Limited Announce Therapeutic Goods Administration Grants Cann GMP License to Manufacture Therapeutic Goods

Cann Group Limited Receives Second Payment from Victorian Government's Regional Jobs Fund Program

Less than half of directors are independent

Office of Drug Control Grants Permit for Manufacture of Medicinal Cannabis Products to Cann Group Limited

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Cann Group Limited Announces Resignation of Mr. Geoffrey Pearce as Non-Executive Director

Cann Group Limited Announces Cann to Begin Recruitment for CBD Phase 3 Clinical Trial

Rua Bioscience Limited (NZSE:RUA) agreed to acquire 8.36% stake in Zalm Therapeutics Ltd from Cann Group Limited (ASX:CAN) for NZD 10 million.

Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now

Chief Financial Officer Greg Bullock has left the company

Full year 2021 earnings released: AU$0.097 loss per share (vs AU$0.12 loss in FY 2020)

Cann Group Limited Revises Revenue Guidance for the Year 2021

Cann Group Limited (ASX:CAN) completed the acquisition of Satipharm Ltd, Satipharm AG and Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT)

Cann Group Limited, Olivia Newton-John Cancer Research Institute and Austin Health Partnered in A Clinical Tria to Assess Medicinal Cannabis for Symptom Management in People with Advanced Cancer

Cann Group Limited (ASX:CAN) entered into a definitive sale agreement to acquire Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT).

First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.06 loss in 1H 2020)

Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn Situation

Cann Group Limited (ASX:CAN) signed a share sale agreement to acquire Satipharm Ltd from Harvest One Cannabis Inc. (TSXV:HVT) for CAD 4 million.

New 90-day high: AU$0.78

Australis Capital Inc. and Cann Group Limited Sign Agreement

Price target lowered to AU$1.12

Cann Group Limited Receives Initial 19,000 Unit Order for Europe

What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To Be

Analysts update estimates

New 90-day high: AU$0.51

Deputy Chairman recently bought AU$55k worth of stock

An unknown buyers acquired 11.84% stake in Cann Group Limited (ASX:CAN) from Aurora Cannabis Inc. (TSX:ACB).

New 90-day low: AU$0.38

Cann Group Limited(ASX:CAN) dropped from S&P Global BMI Index

Deputy Chairman recently bought AU$79k worth of stock

Full year earnings released - AU$0.12 loss per share

New 90-day low - AU$0.45

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 25.9 million.

New 90-day low - AU$0.46

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 14.3 million.

New 90-day low - AU$0.72

Cann Group Limited(ASX:CAN) dropped from S&P/ASX All Ordinaries Index

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

過去基準チェック /06